Anti-TNFR2 monoclonal antibody LBL-019 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose escalation Study.

被引：0
|
作者：
Zhou, Fei
Li, Wei
Chen, Yu
Lin, Jing
Chen, Ling
Zhang, Huishan
Dong, Xiaorong
Tong, Fan
Zhang, Ruiguang
Yin, Yongmei
Liang, Yan
Yang, Nong
Hu, Sheng
Zhuang, Wei
Li, Tao
Cai, Shengli
Zhou, Caicun
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Sch Med, Shanghai, Peoples R China
[2] Tongji Univ, Thorac Canc Inst, Sch Med, Shanghai, Peoples R China
[3] Fujian Canc Hosp, Dept Oncol, Fuzhou, Peoples R China
[4] Fujian Canc Hosp, Fuzhou, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[6] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Peoples R China
[7] Hunan Canc Hosp, Lung Gastrointestinal & Oncol Dept, Changsha, Peoples R China
[8] Hubei Canc Hosp, Dept Internal Med Oncol, Wuhan, Peoples R China
[9] Nanjing Leads Biolabs Co Ltd, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14580
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study
    Li, Qun
    Zhao, Wei
    Wang, Wei
    Chen, Po
    Niu, Zuoxing
    Ni, Shuqin
    Luo, Suxia
    Qiao, Junjing
    Wang, Mingxi
    Li, Yong
    He, Yan
    Liu, Tao
    Li, Tao
    Cai, Shengli
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.
    Moore, Kathleen N.
    Bendell, Johanna C.
    Olszanski, Anthony J.
    Desai, Madhuri
    Jansen, Mendel
    Scheyer, Richard David
    Senaldi, Giorgio
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Beecroft, Claire
    Gao, Bo
    Park, John
    Wilkinson, Kate
    Zhang, Karl
    Yan, Xiangyun
    Lv, Yuan
    CANCER RESEARCH, 2024, 84 (07)
  • [4] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Park, John J.
    Gao, Bo
    Beecroft, Claire
    Wilkinson, Kate Jessica
    Parsonson, Andrew
    Zhang, Karl
    Yan, Xiangyun
    Wang, Ni
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
    Rodon, Jordi
    Tawbi, Hussein A.
    Thomas, Anne L.
    Stoller, Ronald G.
    Turtschi, Christian P.
    Baselga, Jose
    Sarantopoulos, John
    Mahalingam, Devalingam
    Shou, Yaping
    Moles, Melissa A.
    Yang, Lin
    Granvil, Camille
    Hurh, Eunju
    Rose, Kristine L.
    Amakye, Dereck D.
    Dummer, Reinhard
    Mita, Alain C.
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1900 - 1909
  • [6] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [7] Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study
    Yang, Yunpeng
    Zhao, Yuanyuan
    Fang, Wenfeng
    Huang, Yan
    Zhang, Yaxiong
    Ba, Yi
    Wang, Zhen
    Deng, Chao
    Hu, Desheng
    Wang, Wei
    Li, Guiling
    Luo, Suxia
    Fu, Zhichao
    Zhu, Haisheng
    Wang, Huili
    Zhao, Shiwei
    Li, Tao
    Cai, Charles
    Zhang, Li
    CANCER RESEARCH, 2024, 84 (07)
  • [8] Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
    Bauer, Todd M.
    Santoro, Armando
    Lin, Chia-Chi
    Garrido-Laguna, Ignacio
    Joerger, Markus
    Greil, Richard
    Spreafico, Anna
    Yau, Thomas
    Goebeler, Maria-Elisabeth
    Huetter-Kroenke, Marie Luise
    Perotti, Antonella
    Juif, Pierre-Eric
    Lu, Darlene
    Barys, Louise
    Cremasco, Viviana
    Pelletier, Marc
    Evans, Helen
    Fabre, Claire
    Doi, Toshikiko
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (11)
  • [9] A FIRST-IN-HUMAN, MULTICENTER, PHASE 1/2, OPEN-LABEL STUDY OF XTX101 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Powderly, John
    Norman, Teleen
    Duncan, Meghan
    Huber, Martin
    O'Neil, Jennifer
    Patel, Ekta
    Vandross, Andrae
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A549 - A549
  • [10] A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors
    Tolcher, Anthony W.
    Wu, Xiaohua
    Zhang, Jian
    Barve, Minal A.
    Gabrail, Nashat Y.
    Sommerhalder, David
    Rivera, Ildefonso I. Rodriguez
    Wilks, Sharon
    Wu, Yong
    Liu, Rujiao
    Gao, Shuiping
    Valiyil, Akhilkrishna
    Sayi, Ntombizodwa
    Germa, Caroline
    Qi, Charlie
    Chen, Lei
    Yu, Steven
    Yao, Jenny
    Zhu, Xuelian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345